No products in the cart.
TP53 is the gene which encodes for the p53 tumor suppressor protein. TP53 is activated in many forms of cellular stress including carcinogensis and exerts multiple anti-proliferatiuve functions1. TP53 mutations are one of the most common findings in many human cancers and has been proposed as an effective measure of prognosis2.
Typically the prescence of a specific mutation has been correclated with a shorter survival or poor response to treatment. Multiple breast cancer studies have all shown that there was a clear association between mutation and bad prognosis3.
FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY
|Download OUS Datasheet|
IVD is NOT for Sale in the United States but may be available in certain countries outside of the United States, please contact your local distributor for more information.
1. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307–310.
2. Hainaut P, Hollstein M. (2000). p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81–137.
3. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157–1167.
4. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.